{
  "guideline": {
    "id": "PA166328690",
    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Fosphenytoin - HLA-B",
    "objCls": "PGx Association",
    "source": "FDA",
    "version": 0,
    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328690",
    "relatedChemicals": [
      {
        "id": "PA164746820",
        "name": "fosphenytoin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA35056",
        "name": "major histocompatibility complex, class I, B",
        "symbol": "HLA-B"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166324221",
      "name": "Recommendation Annotation PA166324221",
      "population": "HLA-B*15:02 allele positive",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452337680,
        "html": "<p>&quot;May result in higher adverse reaction risk (severe cutaneous reactions). Patients positive for HLA-B*15:02 may be at increased risk of Stevens Johnson Syndrome/Toxic Epidermal necrolysis (SJS/TEN). Consider avoiding fosphenytoin as an alternative to carbamazepine in patients who are positive for HLA-B*15:02. Genotyping is not a substitute for clinical vigilance and patient management.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 positive"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [],
  "version": "2024-03-08-14-34"
}